AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Pure Johnshopkins

Published November 10, 2026

Characterizing the Risks and Benefits of Psychedelics for Depression - Fingerprint

Read the full story at Pure Johnshopkins

Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression · Daniel Meling ·, Rebecca Ehrenkranz ·, Sandeep Nayak.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics